Skip Navigation


Annals of Oncology Advance Access originally published online on November 15, 2005
Annals of Oncology 2006 17(4):719-720; doi:10.1093/annonc/mdj049
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/4/719    most recent
mdj049v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertuzzi, A.
Right arrow Articles by Santoro, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertuzzi, A.
Right arrow Articles by Santoro, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

letter to the editor

High-dose chemotherapy as adjuvant treatment for high-risk primary breast cancer patients

The first 10% of the full text of this article appears below.

In a study recently published in Annals of Oncology, Coombes et al. [1Go] reported the results of a prospective randomized trial comparing a short course of anthracycline-containing chemotherapy followed by high-dose chemotherapy with stem-cell support (HDCT) versus a conventional-dose anthracycline-containing chemotherapy (CDCT) as adjuvant treatment in breast cancer patients with four or more positive axillary lymph nodes. In their experience the authors . . . [Full Text of this Article]

A. Bertuzzi, G. Gullo*, L. Rimassa, L. Castagna and A. Santoro

Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano (Milano), Italy

* (E-mail: giuseppe.gullo@humanitas.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?